Skip to main content

The Importance of Chemotherapy in Treating Triple Negative Breast Cancer

About 10 to 20% of breast cancers are triple negative, one of the most aggressive forms of breast cancer. 三阴性乳腺癌(TNBC)患者的五年生存率为77%,而其他类型乳腺癌患者的五年生存率为93%, 部分原因是,他们不太可能追求生存机会最高的化疗.

In an effort to improve survival rates and health outcomes, 疾病预防控制中心癌症预防和控制司与全国慢性疾病主任协会和健康模拟公司Kognito进行了合作, the leading developer of health education simulations, to create “Talk to Someone: Triple Negative Breast Cancer.”

“与人交谈:三阴性乳腺癌”是一个在线和移动应用程序,三阴性乳腺癌患者可以与琳达进行互动对话, a virtual TNBC survivor. Users lead the conversation by posing their questions about TNBC, chemotherapy, life during treatment, and survivorship to Linda. The objectives of the conversation are for patients to better understand their diagnosis, better understand advantages of chemotherapy, and to know what to expect from treatment, in order to raise motivation to pursue chemotherapy.

“Talk to Someone: Triple Negative Breast Cancer”是一个在线的移动应用程序,供公众和肿瘤科医生为新诊断的患者开电子处方.

To talk with Linda about diagnosis and treatment, Click Here, or download the app on the App Store or Google Play Store.